CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
CalciMedica Inc. (Nasdaq: CALC) announced the acceptance of a late-breaking abstract for a plenary presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. The presentation will be given by Prof. Robert Sutton from the University of Liverpool and Liverpool University Hospitals NHS Foundation Trust on October 30, 2024 at 10:00-10:15 a.m. ET in the Grand Ballroom.
Prof. Sutton is the chair of the Steering Committee for the CARPO acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS) clinical trial. The presentation is part of the Simultaneous Plenary Session 4A and is listed as Abstract #64. The abstract authors include researchers from various institutions, including CalciMedica, Inc.
CalciMedica Inc. (Nasdaq: CALC) ha annunciato l'accettazione di un abstract dell'ultimo minuto per una presentazione plenaria durante il Meeting Scientifico Annuale dell'American College of Gastroenterology (ACG) 2024. La presentazione sarà tenuta dal Prof. Robert Sutton dell'Università di Liverpool e dal Liverpool University Hospitals NHS Foundation Trust il 30 ottobre 2024 dalle 10:00 alle 10:15 ET nella Grand Ballroom.
Il Prof. Sutton è il presidente del Comitato di Direzione per il trial clinico CARPO sulla pancreatite acuta (AP) con sindrome da risposta infiammatoria sistemica (SIRS). La presentazione fa parte della Sessione Plenaria Simultanea 4A ed è inserita come Abstract #64. Gli autori dell'abstract includono ricercatori di varie istituzioni, tra cui CalciMedica, Inc.
CalciMedica Inc. (Nasdaq: CALC) anunció la aceptación de un resumen de última hora para una presentación plenaria en el Encuentro Científico Anual del American College of Gastroenterology (ACG) 2024. La presentación será realizada por el Prof. Robert Sutton de la Universidad de Liverpool y el Liverpool University Hospitals NHS Foundation Trust el 30 de octubre de 2024 de 10:00 a 10:15 a.m. ET en el Gran Salón.
El Prof. Sutton es el presidente del Comité Directivo del ensayo clínico CARPO sobre pancreatitis aguda (AP) con síndrome de respuesta inflamatoria sistémica (SIRS). La presentación es parte de la Sesión Plenaria Simultánea 4A y está listada como Resumen #64. Los autores del resumen incluyen investigadores de varias instituciones, incluida CalciMedica, Inc.
CalciMedica Inc. (Nasdaq: CALC)는 2024년 미국 위장병학회(ACG) 연례 학술 회의에서 기획 발표를 위한 늦게 발표된 초록의 수락을 발표했습니다. 발표는 로버트 Sutton 교수가 리버풀 대학교 및 리버풀 대학교 병원 NHS 재단에서 진행하며, 2024년 10월 30일 오전 10시부터 10시 15분(ET)까지 그랜드 볼룸에서 진행됩니다.
Sutton 교수는 급성 췌장염(AP) 및 동반된 전신 염증 반응 증후군(SIRS) 임상 시험을 위한 자문위원회 의장입니다. 이 발표는 동시 기획 세션 4A의 일환으로 진행되며 초록 번호는 #64로 되어 있습니다. 초록 저자에는 CalciMedica, Inc.를 포함한 여러 기관의 연구원들이 참여하고 있습니다.
CalciMedica Inc. (Nasdaq: CALC) a annoncé l'acceptation d'un résumé de dernière minute pour une présentation plénière lors de la Réunion Scientifique Annuelle de l'American College of Gastroenterology (ACG) 2024. La présentation sera donnée par le Prof. Robert Sutton de l'Université de Liverpool et du Liverpool University Hospitals NHS Foundation Trust le 30 octobre 2024 de 10h00 à 10h15 (ET) dans le Grand Salon.
Le Prof. Sutton est le président du Comité de Pilotage de l'
CalciMedica Inc. (Nasdaq: CALC) gab die Annahme eines späten Abstracts für eine Plenarpräsentation auf dem Jahreswissenschaftlichen Treffen des American College of Gastroenterology (ACG) 2024 bekannt. Die Präsentation wird von Prof. Robert Sutton von der Universität Liverpool und dem Liverpool University Hospitals NHS Foundation Trust am 30. Oktober 2024 von 10:00 bis 10:15 Uhr ET im Grand Ballroom gehalten.
Prof. Sutton ist der Vorsitzende des Lenkungsausschusses der CARPO-Studie zu akuter Pankreatitis (AP) mit begleitendem systemischen entzündlichen Antwortsyndrom (SIRS). Die Präsentation ist Teil der Simultaneous Plenary Session 4A und ist als Abstract #64 gelistet. Zu den Autoren des Abstracts gehören Forscher aus verschiedenen Institutionen, einschließlich CalciMedica, Inc.
- Acceptance of a late-breaking abstract for plenary presentation at a major scientific meeting
- Presentation by the chair of the Steering Committee for the CARPO clinical trial
- Involvement of prominent researchers from multiple institutions in the abstract
- None.
Details for the presentation are as follows:
Presenter: Prof. Robert Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of
Session Title: Simultaneous Plenary Session 4A
Session Date and Time: Wednesday, October 30, 10:00-10:15 a.m. ET
Location: Grand Ballroom
Abstract #: 64
Abstract Authors: Prof. Robert Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, Liverpool Pancreatitis Research Group, Institute of Systems, Molecular and Integrative Biology, University of
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
Forward-Looking Statements
This communication contains forward-looking statements which include, but are not limited to, CalciMedica's ongoing and planned clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2b CARPO trial of Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances. Risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2023, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-late-breaker-plenary-presentation-at-the-american-college-of-gastroenterology-acg-2024-annual-scientific-meeting-302277217.html
SOURCE CalciMedica, Inc.
FAQ
When and where will CalciMedica's (CALC) presentation take place at the ACG 2024 Annual Scientific Meeting?
Who will be presenting CalciMedica's (CALC) late-breaking abstract at the ACG 2024 meeting?
What is the focus of CalciMedica's (CALC) CARPO clinical trial presented at ACG 2024?
What is CalciMedica's (CALC) main area of research and development?
